WO2018217809A1 - Pyrazole magl inhibitors - Google Patents

Pyrazole magl inhibitors Download PDF

Info

Publication number
WO2018217809A1
WO2018217809A1 PCT/US2018/033964 US2018033964W WO2018217809A1 WO 2018217809 A1 WO2018217809 A1 WO 2018217809A1 US 2018033964 W US2018033964 W US 2018033964W WO 2018217809 A1 WO2018217809 A1 WO 2018217809A1
Authority
WO
WIPO (PCT)
Prior art keywords
solvate
hydrate
oxide
stereoisomer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/033964
Other languages
English (en)
French (fr)
Inventor
Cheryl A. Grice
Olivia D. Weber
Daniel J. Buzard
Michael B. SHAGHAFI
John J. M. Wiener
Justin S. Cisar
Katharine K. Duncan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lundbeck La Jolla Research Center Inc
Original Assignee
Abide Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CR20190537A priority Critical patent/CR20190537A/es
Priority to JP2019565399A priority patent/JP7162622B2/ja
Priority to ES18805515T priority patent/ES3005265T3/es
Priority to CA3065898A priority patent/CA3065898A1/en
Priority to PE2019002453A priority patent/PE20200293A1/es
Priority to RU2019137094A priority patent/RU2019137094A/ru
Priority to CN201880033866.9A priority patent/CN110678177B/zh
Priority to MX2019014041A priority patent/MX2019014041A/es
Priority to US16/615,746 priority patent/US11149037B2/en
Priority to BR112019024488-3A priority patent/BR112019024488A2/pt
Priority to EP18805515.6A priority patent/EP3634404B1/en
Priority to KR1020197037406A priority patent/KR20200010366A/ko
Application filed by Abide Therapeutics Inc filed Critical Abide Therapeutics Inc
Priority to AU2018273888A priority patent/AU2018273888A1/en
Priority to EA201992504A priority patent/EA201992504A1/ru
Publication of WO2018217809A1 publication Critical patent/WO2018217809A1/en
Priority to DO2019000295A priority patent/DOP2019000295A/es
Priority to CONC2019/0013016A priority patent/CO2019013016A2/es
Priority to PH12019502646A priority patent/PH12019502646A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • Monoacylglycerol lipase is an enzyme responsible for hydrolyzing
  • endocannabinoids such as 2-AG (2-arachidonoylglycerol), an arachidonate based lipid, in nervous system.
  • Fatty acid amide hydrolase (FAAH) is another enzyme responsible for hydrolyzing endocannabinoids such as anandamide.
  • This disclosure provides, for example, compounds and compositions which are modulators of MAGL, and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active ingredient.
  • the disclosure also provides for the use of disclosed compounds as medicaments and/or in the manufacture of medicaments for the inhibition of MAGL activity in warm-blooded animals such as humans.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • R 2 is H or C h alky!
  • A is N or C(H);
  • X is -0-, -N(R 16 )-, or -CH 2 N(R 16 )CH 2 -;
  • Y is -CH 2 - or -C(O)-;
  • Z is -S-, -0-, or -N(R 20 )-;
  • R 4 is H, halogen, -OR 7 , Ci -6 alkyl, Ci -6 alkyl-OH, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -0-C 3- scycloalkyl, -0-C 3-8 cycloalkyl-OH, -N(H)-Ci -6 alkyl-C0 2 H, -S0 2 R 17 , -C0 2 R 8 , -C(0) R 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -Ci- 6 alkyl-C 2-9 heterocycloalkyl, C6-io ryl, Ci.
  • R 5 is H, -CN, halog Ci- 6 haloalkyl, Ci-ehaloalkoxy, or phenyl;
  • R 6 is H, halogen, or
  • R 7 is H, Ci -6 alkyl, Ci -6 haloalkyl, C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, C 6- i 0 aryl, or Ci.
  • each R 8 and each R 9 are independently selected from H and or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;
  • R iU is -O-Ci-ehaloalkyl, -0-Ci -6 alkyl-C0 2 H, -0-C 3-8 cycloalkyl, -0-C 3-8 cycloalkyl-C0 2 H, -N(H)-
  • R 12 is H, halogen, or Ci -6 alkyl
  • R 13 is H or C h alky.
  • each R 14 is independently selected from halogen, -OH, oxo, Ci- 6 haloalkyl, Ci -6 alkoxy, -Ci -6 alkyl-OH, C 3-8 cycloalkyl, -C0 2 R 8 , -C(0) R 8 R 9 , -C(0)-Ci -6 alkyl, -C(0)-Ci -6 alkyl-OH, -S0 2 -Ci -6 alkyl, -N(R 8 )S0 2 -Ci -6 alkyl, and -N(R 8 )C(0)-Ci -6 alkyl;
  • R 15 is Ci -6 alkyl or C 3-8 cycloalkyl
  • R 16 is H, Ci -6 alkyl, -C(0)-Ci -6 alkyl, or -CH 2 C0 2 H;
  • R 17 is Ci- 6 alkyl or C 3-8 cycloalkyl
  • R 18 and R 19 are independently selected from H and Ci -6 alkyl, wherein R 18 and R 19 are not both H;
  • R 20 is H or Ci -6 alkyl
  • v 0 or 1
  • n 0 or 1
  • n 0 or 1
  • p 0, 1, or 2;
  • q 0, 1, or 2;
  • w 1 or 2;
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, p is 1, and w is 1.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, p is 1, and w is 1.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is
  • n is 1
  • p is 1
  • w is 2.
  • n is 1
  • p is 1
  • w is 2.
  • m is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein m is
  • n is 1, p is 0, and w is 1.
  • R 3 is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein m is 1, n is 1, q is 1, and p is 1.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, q is 0, and p is 2.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, q is 1, and p is 0.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein Z is -S-.
  • Y is -CH 2 -.
  • Y is -CH 2 -.
  • Y is -C(O)-.
  • Y is -C(O)-.
  • R 3 is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 3 is .
  • R 3 is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 6 is H.
  • R 6 is H.
  • R is a pharmaceutically acceptable salt thereof, wherein R .
  • R is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,
  • R is In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein Z is -S-. In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or
  • R 13 is H.
  • R 12 is H.
  • R i is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 13 is H.
  • R 3 is In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein v is 0. In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein v is 1. In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein X is -0-.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein X is - N(CH 3 )-.
  • R 3 is .
  • R 19 is Ci- 6 alkyl.
  • R 18 hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R is H and R 19 is -CH 3 .
  • R 19 is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 6 is H.
  • in another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , Ci -6 alkyl- OH, -N(H)-Ci -6 alkyl-C0 2 H, C 2 - 6 alkynyl, Ci -6 haloalkyl, -C0 2 R 8 , -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2- gheterocycloalkyl, C6-ioaryl, or Ci.gheteroaryl, wherein C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, C 6- l oaryl, or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 .
  • R 4 is halogen, -OR 7 , Ci -6 alkyl- OH, -N(H)
  • R 4 is halogen, -OR 7 , -N(H)-Ci -6 alkyl-C0 2 H, Ci. 6 haloalkyl, -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, or Ci.gheteroaryl, wherein C 2- gheterocycloalkyl or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 .
  • R 4 is halogen.
  • R 4 is -CI.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)-Ci -6 alkyl-C0 2 H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 .
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 7 is unsubstituted C 3- 8 cycloalkyl or C 6- i 0 aryl optionally substituted with halogen.
  • In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 10 is -O-Ci.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 10 is -N(H)-Ci- 6 alkyl-C0 2 H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 10 is -N(H)CH 2 C0 2 H, -N(H)CH 2 CH 2 C0 2 H, or -N(H)CH 2 CH 2 CH 2 C0 2 H.
  • R 5 is H, -CN, halogen, Ci -6 alkyl, Ci -6 haloalkyl, or
  • Ci -6 haloalkoxy In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is H. In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is halogen. In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is -CI. In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or
  • R 5 is Ci -6 haloalkyl.
  • R 5 is Ci -6 haloalkyl.
  • R 5 is -CF 3 .
  • R 5 is -CF 3 .
  • a compound of Formula (I) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or
  • R 1 is -N(R 2 )C(0)R 15 .
  • R 1 is -N(R 2 )C(0)R 15 .
  • R 1 is -N(R 2 )C(0)R 15 .
  • R 1 is -N(R 2 )C(0)R 15 .
  • R 1 is -N(R 2 )C(0)R 15 .
  • R 1 is -N(R 2 )C(0)R 15 .
  • R 1 is -N(R 2 )C(0)R 15 .
  • R 1 is -N(R 2 )C(0)R 15 .
  • R 1 is -N(R 2 )C(0)R 15 .
  • R 1 is -N(R 2 )C(0)R 15 .
  • R 1 is -N(R 2 )C(0)R 15 .
  • R 1 is -N(R 2 )C(0)R 15 .
  • R 1 is -N(R 2 )C(0)R 15 .
  • R 1 is -N(
  • R 2 is H.
  • R 15 is Ci -6 alkyl.
  • R 15 is a compound of Formul (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 15 is -CH 3 .
  • R 1 -N(H)S0 2 R 15 is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 -N(H)S0 2 R 15 .
  • composition comprising a compound of Formula (I) described herein, or a solvate, hydrate, tautomer, N-oxide, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
  • in another embodiment is a method of treating pain in a patient in need thereof, comprisin administering to the patient a therapeutically effective amount of a compound of Formula (I) described herein, or a solvate, hydrate, tautomer, N-oxide, or a pharmaceutically acceptable salt thereof.
  • a method of treating neuropathic pain in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) described herein, or a solvate, hydrate, tautomer, N-oxide, or a pharmaceutically acceptable salt thereof.
  • in another embodiment is a method of treating inflammatory pain in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) described herein, or a solvate, hydrate, tautomer, N-oxide, or a pharmaceutically acceptable salt thereof.
  • a method of treating a disease or disorder in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a compound of Formula (I) described herein, or a solvate, hydrate, tautomer, N-oxide, or a pharmaceutically acceptable salt thereof, wherein the disease is selected from migraine, epilepsy/seizure disorder, neuromyelitis optica ( ⁇ ), Tourette syndrome, persistent motor tic disorder, persistent vocal tic disorder, and abdominal pain associated with irritable bowel syndrome.
  • a compound of Formula (I) described herein or a solvate, hydrate, tautomer, N-oxide, or a pharmaceutically acceptable salt thereof
  • the disease is selected from migraine, epilepsy/seizure disorder, neuromyelitis optica ( ⁇ ), Tourette syndrome, persistent motor tic disorder, persistent vocal tic disorder, and abdominal pain associated with irritable bowel syndrome.
  • in another embodiment is a method of treating migraine in a patient in need thereof, comprising administering to the patient therapeutically effective amount of a compound of Formula (I) described herein, or a solvate, hydrate, tautomer, N-oxide, or a pharmaceutically acceptable salt thereof.
  • a method of treating epilepsy/seizure disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) described herein, or a solvate, hydrate, tautomer, N-oxide, or a pharmaceutically acceptable salt thereof.
  • NMO neuromyelitis optica
  • a method of treating neuromyelitis optica (NMO) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) described herein, or a solvate, hydrate, tautomer, N-oxide, or a pharmaceutically acceptable salt thereof.
  • a method of treating Tourette syndrome in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) described herein, or a solvate, hydrate, tautomer, N- oxide, or a pharmaceutically acceptable salt thereof.
  • in another embodiment is a method of treating persistent motor tic disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) described herein, or a solvate, hydrate, tautomer, N-oxide, or a pharmaceutically acceptable salt thereof.
  • a method of treating persistent vocal tic disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula (I) described herein, or a solvate, hydrate, tautomer, N-oxide, or a pharmaceutically acceptable salt thereof.
  • in another embodiment is a method of treating abdominal pain associated with irritable bowel syndrome in a patient in need thereof, comprising administering to the patient a
  • This disclosure is directed, at least in part, to modulators or inhibitors of MAGL.
  • modulators or inhibitors of MAGL For example, provided herein are compounds capable of inhibiting MAGL.
  • composition, method, or process, or the like, described herein may "consist of or "consist essentially of the described features.
  • Ci-C x includes C 1 -C 2 , C 1 -C 3 . . . Ci-C x .
  • Ci-C x refers to the number of carbon atoms that make up the moiety to which it designates (excluding optional substituents).
  • Amino refers to the -NH 2 radical.
  • Niro refers to the -N0 2 radical.
  • Oxa refers to the -O- radical.
  • Alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to fifteen carbon atoms (e.g. , C 1 -C 15 alkyl).
  • an alkyl comprises one to thirteen carbon atoms (e.g. , C 1 -C 13 alkyl).
  • an alkyl comprises one to eight carbon atoms (e.g., Ci-C 8 alkyl).
  • an alkyl comprises one to six carbon atoms (e.g., Ci-C 6 alkyl).
  • an alkyl comprises one to five carbon atoms (e.g., C 1 -C5 alkyl). In other embodiments, an alkyl comprises one to four carbon atoms (e.g., C 1 -C 4 alkyl). In other
  • an alkyl comprises one to three carbon atoms (e.g., C 1 -C 3 alkyl). In other words, C 1 -C 3 alkyl.
  • an alkyl comprises one to two carbon atoms (e.g., Ci-C 2 alkyl).
  • Ci-C 2 alkyl e.g., Ci-C 2 alkyl
  • an alkyl comprises one carbon atom (e.g., Ci alkyl). In other embodiments, an alkyl comprises five to fifteen carbon atoms (e.g., C5-C 15 alkyl). In other embodiments, an alkyl comprises five to eight carbon atoms (e.g., C 5 -C 8 alkyl). In other embodiments, an alkyl comprises two to five carbon atoms (e.g., C 2 -C 5 alkyl). In other embodiments, an alkyl comprises three to five carbon atoms (e.g., C 3 -C5 alkyl).
  • the alkyl group is selected from methyl, ethyl, 1 -propyl ( ⁇ -propyl), 1 -methyl ethyl (z ' so-propyl), 1 -butyl ( «-butyl), 1 -methylpropyl (sec- butyl), 2-methylpropyl (iso-buty ⁇ ), 1, 1 -dimethyl ethyl (tert-butyl), and 1-pentyl ( «-pentyl).
  • the alkyl is attached to the rest of the molecule by a single bond.
  • an alkyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(0)-R f , -N(R a ) 2 , - C(0)R a , -C(0)OR a , -C(0)N(R a ) 2 , -N(R a )C(0)OR f , -OC(0)- R a R f , -N(R a )C(0)R f , -N(R a )S(0) t R f (where t is 1 or 2), -S(0) t OR a (where t is 1 or 2), -S(0) t R f (where t is 1 or 2) and -S(0) t N(R a )
  • Alkoxy refers to a radical bonded through an oxygen atom of the formula -O-alkyl, where alkyl is an alkyl chain as defined above.
  • alkenyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and having from two to twelve carbon atoms. In certain embodiments, an alkenyl comprises two to eight carbon atoms. In other embodiments, an alkenyl comprises two to four carbon atoms. The alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-l-enyl (i. e., allyl), but-l-enyl, pent-l-enyl, penta-l,4-dienyl, and the like.
  • ethenyl i.e., vinyl
  • prop-l-enyl i. e., allyl
  • but-l-enyl pent-l-enyl, penta-l,4-dienyl, and the like.
  • an alkenyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(0)-R f , -N(R a ) 2 , -C(0)R a , -C(0)OR a , -C(0)N(R a ) 2 , -N(R a )C(0)OR f , -OC(0)- R a R f , - N(R a )C(0)R f , -N(R a )S(0) t R f (where t is 1 or 2), -S(0) t OR a (where t is 1 or 2), -S(0) t R f (where t is 1 or 2) and -S(0) t N(R a )
  • Alkynyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond, having from two to twelve carbon atoms.
  • an alkynyl comprises two to eight carbon atoms.
  • an alkynyl has two to four carbon atoms.
  • the alkynyl is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
  • an alkynyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(0)-R f , -N(R a ) 2 , -C(0)R a , -C(0)OR a , - C(0)N(R a ) 2 , -N(R a )C(0)OR f , -OC(0)- R a R f , -N(R a )C(0)R f , -N(R a )S(0) t R f (where t is 1 or 2), - S(0) t OR a (where t is 1 or 2), -S(0) t R f (where t is 1 or 2) and -S(0) t N(R a
  • Aryl refers to a radical derived from an aromatic monocyclic or multicyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom.
  • the aromatic monocyclic or multicyclic hydrocarbon ring system contains only hydrogen and carbon from six to eighteen carbon atoms, where at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) ⁇ -electron system in accordance with the Hiickel theory.
  • the ring system from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin and naphthalene.
  • aryl or the prefix “ar-” (such as in “aralkyl”) is meant to include aryl radicals optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, haloalkyl, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R -OR a , -R -OC(0)-R a , -R -OC(0)-OR a , -R -OC(0)-N(R a ) 2 , -R - N(R a ) 2 , -R -C(0)R a , -R -C(0)OR a , -R -C(0)N(R a ) 2 , -R -0-R
  • Aryloxy refers to a radical bonded through an oxygen atom of the formula -O-aryl, where aryl is as defined above.
  • Aralkyl refers to a radical of the formula -R c -aryl where R c is an alkylene chain as defined above, for example, methylene, ethylene, and the like.
  • the alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain.
  • the aryl part of the aralkyl radical is optionally substituted as described above for an aryl group.
  • Aralkyloxy refers to a radical bonded through an oxygen atom of the formula -O-aralkyl, where aralkyl is as defined above.
  • alkenyl refers to a radical of the formula -R d -aryl where R d is an alkenylene chain as defined above.
  • the aryl part of the aralkenyl radical is optionally substituted as described above for an aryl group.
  • the alkenylene chain part of the aralkenyl radical is optionally substituted as defined above for an alkenylene group.
  • Aralkynyl refers to a radical of the formula -R e -aryl, where R e is an alkynylene chain as defined above.
  • the aryl part of the aralkynyl radical is optionally substituted as described above for an aryl group.
  • the alkynylene chain part of the aralkynyl radical is optionally substituted as defined above for an alkynylene chain.
  • Cycloalkyl refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which includes fused or bridged ring systems, having from three to fifteen carbon atoms.
  • a cycloalkyl comprises three to ten carbon atoms.
  • a cycloalkyl comprises five to seven carbon atoms. The cycloalkyl is attached to the rest of the molecule by a single bond.
  • Cycloalkyls are saturated, (i.e., containing single C-C bonds only) or partially unsaturated (i.e., containing one or more double bonds or triple bonds.)
  • monocyclic cycloalkyls include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • a cycloalkyl comprises three to eight carbon atoms (e.g., C 3 -C 8 cycloalkyl).
  • a cycloalkyl comprises three to seven carbon atoms (e.g., C 3 -C 7 cycloalkyl). In other embodiments, a cycloalkyl comprises three to six carbon atoms (e.g., C 3 -C 6 cycloalkyl). In other embodiments, a cycloalkyl comprises three to five carbon atoms (e.g., C 3 -C 5 cycloalkyl). In other embodiments, a cycloalkyl comprises three to four carbon atoms (e.g., C 3 -C 4 cycloalkyl).
  • a partially unsaturated cycloalkyl is also referred to as "cycloalkenyl.”
  • monocyclic cycloalkenyls include, e.g., cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
  • Polycyclic cycloalkyl radicals include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptanyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.
  • cycloalkyl is meant to include cycloalkyl radicals that are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, haloalkyl, oxo, thioxo, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R -OR a , -R -OC(0)-R a , -R -OC(0)-OR a , -R -OC(0)-N(R a ) 2 , -R -N(R a ) 2 , -R - C(0)R a , -R -C(0)OR a , -R -C(0)N(R a ) 2 , -R -0-
  • Halo or “halogen” refers to bromo, chloro, fluoro or iodo substituents.
  • Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above.
  • Haloalkoxy refers to an alkoxy radical, as defined above, that is substituted by one or more halo radicals, as defined above.
  • Fluoroalkyl refers to an alkyl radical, as defined above, that is substituted by one or more fluoro radicals, as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1 -fluoromethyl -2 -fluoroethyl, and the like.
  • the alkyl part of the fluoroalkyl radical are optionally substituted as defined above for an alkyl group.
  • Heterocycloalkyl refers to a stable 3- to 18-membered non-aromatic ring radical that comprises two to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur. Unless stated otherwise specifically in the specification, the heterocycloalkyl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which include fused, spiro, or bridged ring systems. The heteroatoms in the heterocycloalkyl radical are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocycloalkyl radical is partially or fully saturated.
  • the heterocycloalkyl is attached to the rest of the molecule through any atom of the ring(s).
  • heterocycloalkyl radicals include, but are not limited to, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl,
  • octahydroisoindolyl 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl,
  • heterocycloalkyl is meant to include heterocycloalkyl radicals as defined above that are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, haloalkyl, oxo, thioxo, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroaryl alkyl, -R -OR a , -R -OC(0)-R a , -R -OC(0)-OR a , -R - OC(0)-N(R a ) 2 , -R -N(R a ) 2 , -R -C(0)R a
  • heteroaryl refers to a radical derived from a 3 - to 18-membered aromatic ring radical that comprises one to seventeen carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur.
  • the heteroaryl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) ⁇ -electron system in accordance with the Hiickel theory.
  • Heteroaryl includes fused or bridged ring systems.
  • the heteroatom(s) in the heteroaryl radical is optionally oxidized.
  • One or more nitrogen atoms, if present, are optionally quaternized.
  • the heteroaryl is attached to the rest of the molecule through any atom of the ring(s).
  • heteroaryl is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, haloalkyl, oxo, thioxo, cyano, nitro, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -R -OR a , -R -OC(0)-R a , -R - OC(0)-OR a , -R -OC(0)-N(R a ) 2 , -R -N(R a ) 2 , -R -C(0)R a , -R -C(0)OR a , -R -C(0)N(R a ) 2 , -R -R -C(0)OR a , -R
  • N-heteroaryl refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical.
  • An N-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
  • C-heteroaryl refers to a heteroaryl radical as defined above and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a carbon atom in the heteroaryl radical.
  • a C-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
  • Heteroaryloxy refers to radical bonded through an oxygen atom of the formula -O- heteroaryl, where heteroaryl is as defined above.
  • Heteroarylalkyl refers to a radical of the formula -R c -heteroaryl, where R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom.
  • heteroarylalkyl radical is optionally substituted as defined above for an alkylene chain.
  • the heteroaryl part of the heteroarylalkyl radical is optionally substituted as defined above for a heteroaryl group.
  • Heteroarylalkoxy refers to a radical bonded through an oxygen atom of the formula -O- R c -heteroaryl, where R c is an alkylene chain as defined above. If the heteroaryl is a
  • the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom.
  • the alkylene chain of the heteroarylalkoxy radical is optionally substituted as defined above for an alkylene chain.
  • the heteroaryl part of the heteroarylalkoxy radical is optionally substituted as defined above for a heteroaryl group.
  • the compounds disclosed herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that are defined, in terms of absolute stereochemistry, as (R)- or (S)-. Unless stated otherwise, it is intended that all stereoisomeric forms of the compounds disclosed herein are contemplated by this disclosure.
  • this disclosure includes both E and Z geometric isomers (e.g., cis or trans?) Likewise, all possible isomers, as well as their racemic and optically pure forms, and all tautomeric forms are also intended to be included.
  • the term "geometric isomer” refers to E or Z geometric isomers (e.g., cis or trans) of an alkene double bond.
  • the term “geometric isomer” refers to E or Z geometric isomers (e.g., cis or trans) of an alkene double bond.
  • positional isomer refers to structural isomers around a central ring, such as ortho-, meta-, and para- isomers around a benzene ring.
  • a "tautomer” refers to a molecule wherein a proton shift from one atom of a molecule to another atom of the same molecule is possible.
  • the compounds presented herein exist as tautomers.
  • a chemical equilibrium of the tautomers will exist. The exact ratio of the tautomers depends on several factors, including physical state, temperature, solvent, and pH.
  • Optional or “optionally” means that a subsequently described event or circumstance may or may not occur and that the description includes instances when the event or circumstance occurs and instances in which it does not.
  • optionally substituted aryl means that the aryl radical are or are not substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
  • “Pharmaceutically acceptable salt” includes both acid and base addition salts.
  • pharmaceutically acceptable salt of any one of the pyrazole compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms.
  • Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts, and pharmaceutically acceptable base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.
  • acetic acid trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid,/?-toluenesulfonic acid, salicylic acid, and the like.
  • Exemplary salts thus include sulfates, pyrosulfates, bi sulfates, sulfites, bi sulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinate suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like. Also contemplated are salts of amino acids, such as arginates, glu
  • Acid addition salts of basic compounds are prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt.
  • “Pharmaceutically acceptable base addition salt” refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. In some embodiments, pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, for example, isopropyl amine, trimethylamine, diethylamine, tri ethyl amine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexyl amine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. See Berg
  • treatment or “treating” or “palliating” or “ameliorating” are used interchangeably herein. These terms refer to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit.
  • therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
  • a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient is still afflicted with the underlying disorder.
  • the compositions are administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has not been made.
  • the compounds are inhibitors of MAGL.
  • the compounds of Formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (II), or (Im) described herein, and compositions comprising these compounds, are useful for the treatment of pain.
  • the compounds of Formula (I), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (H), or (Im) described herein, and compositions comprising these compounds, are useful for the treatment of pain, mutiple sclerosis, Alzheimer's disease, and/or inflammatory bowel disease.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • A is N or C(H);
  • X is -0-, -N(R 16 )-, or -CH 2 N(R 16 )CH 2 -;
  • Y is -CH 2 - or -C(O)-;
  • Z is -S-, -0-, or -N(R 20 )-;
  • R 4 is H, halogen, -OR 7 , Ci -6 alkyl, Ci -6 alkyl-OH, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -0-C 3- scycloalkyl, -0-C 3-8 cycloalkyl-OH, -N(H)-Ci -6 alkyl-C0 2 H, -S0 2 R 17 , -C0 2 R 8 , -C(0) R 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -Ci- 6 alkyl-C 2-9 heterocycloalkyl, C6-io ryl, Ci.
  • R 5 is H, -CN, halog Ci-ehaloalkyl, Ci- 6 haloalkoxy, or phenyl;
  • R 6 is H, halogen, or
  • R 7 is H, Ci -6 alkyl, Ci -6 haloalkyl, C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, C 6- i 0 aryl, or Ci.
  • each R 8 and each R 9 are independently selected from H and or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;
  • R 10 is -0-Ci -6 haloalkyl, -0-Ci -6 alkyl-C0 2 H, -0-C 3-8 cycloalkyl, -0-C 3-8 cycloalkyl-C0 2 H, -N(H)-
  • R 12 is H, halogen, or
  • R 13 is H or Ci -6 alkyl
  • each R 14 is independently selected from halogen, -OH, oxo, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 alkoxy, -Ci -6 alkyl-OH, C 3-8 cycloalkyl, -C0 2 R 8 , -C(0) R 8 R 9 , -C(0)-Ci -6 alkyl, -C(0)-Ci -6 alkyl-OH, -S0 2 -Ci -6 alkyl, -N(R 8 )S0 2 -Ci -6 alkyl, and -N(R 8 )C(0)-Ci -6 alkyl;
  • R 15 is Ci -6 alkyl or C 3-8 cycloalkyl
  • R 16 is H, Ci -6 alkyl, -C(0)-Ci -6 alkyl, or -CH 2 C0 2 H; R is Ci- 6 alkyl or C3- 8 cycloalkyl;
  • R 18 and R 19 are independently selected from H and wherein R 18 and R 19 are not both H;
  • R 20 is H or C h alky.
  • v is 0 or 1 ;
  • n 0 or 1 ;
  • n 0 or 1 ;
  • p 0, 1, or 2;
  • q 0, 1, or 2;
  • w 1 or 2;
  • a compound of Formula (I), or a solvate, hydrate, tautomer, ⁇ - oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 .
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is Ci -6 alkyl.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is Ci- 6 alkyl.
  • In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is -CH 3 .
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is -CH 3 .
  • R 1 is -N(CH 3 )C(0)R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is - CH 3 .
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is C 3-8 Cycloalkyl.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 18 is -CH 3 and R 19 is H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 19 is Ci -6 alkyl.
  • embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 12 is H and R 13 is H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is and R 13 is H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, p is 1, and w is 1.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, p is 1, and w is 1.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is
  • n is 1
  • p is 1
  • w is 2.
  • n is 1
  • p is 1
  • w is 2.
  • m is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein m is
  • n is 1, p is 0, and w is 1.
  • R 3 is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 3 is
  • a pharmaceutically acceptable salt thereof wherein m is 1, n is 1, q is 1, and p is 1.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 0, n is 1, q is 2, and p is 1.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, q is 0, and p is 2.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, q is 1, and p is 0.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 0, n is 0, q is 2, and p is 1.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is H and R 13 is H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is Ci- 6 alkyl and R 13 is H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is -CH 3 and R 13 is H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is H and R 13 is -CH 3 .
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is and R 13 is Ci- 6 alkyl.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is Ci -6 alkyl and R 13 is H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is -CH 3 and R 13 is H.
  • X is -N(CH 3 )-.
  • X is -N(CH 3 )-.
  • X is -N(CH 3 )-.
  • X is -CH 2 N(R 16 )CH 2 -.
  • X is -CH 2 N(R 16 )CH 2 -.
  • X is -CH 2 N(R 16 )CH 2 -.
  • X is -CH 2 N(H)CH 2 -.
  • X is -CH 2 N(H)CH 2 -.
  • a compound of Formula (I) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or
  • X is -CH 2 N(CH 3 )CH 2 -.
  • v is 0.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein v is 1.
  • [0057] in another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , C 1 .
  • in another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , -N(H)-Ci -6 alkyl-C0 2 H, Ci- 6 haloalkyl, -C(0)NR 8 R 9 , C 3 - 8 cycloalkyl, C 2 - 9 heterocycloalkyl, or Ci.gheteroaryl, wherein C 2- gheterocycloalkyl or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 .
  • R 4 is -CI.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)-Ci -6 alkyl-C0 2 H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 C0 2 H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is - N(H)CH 2 CH 2 C0 2 H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is - N(H)CH 2 CH 2 CH 2 C0 2 H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is unsubstituted C 3- 8 cycloalkyl or C 6- i 0 aryl optionally substituted with halogen.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl optionally substituted with halogen.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl substituted with halogen.
  • R 4 is C 2 - 9 heterocycloalkyl optionally substituted with 1 or 2 R 14 .
  • R 4 is C 4 - 5 heterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 4 - 5 heterocycloalkyl is a monocyclic heterocycloalkyl selected from pyrrolidine, piperidine, piperazine, and morpholine.
  • R 4 is Cs-gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-gheterocycloalkyl is a bicyclic heterocycloalkyl.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is Cs-gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-gheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is "
  • in another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C 2- 9 heteroaryl optionally substituted with 1 or 2 R 14 , wherein the C 2-9 heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine, indole, benzothiophene, benzofuran, and imidazopyridine.
  • R 4 is C 2- 9 heteroaryl optionally substituted with 1 or 2 R 14 , wherein the C 2-9 heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine,
  • R 5 is -CH 3 .
  • R 5 is -CH 3 .
  • a compound of Formula (I) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or
  • R 5 is Ci-6haloalkyl.
  • R 5 is Ci-6haloalkyl.
  • R 5 is -CF 3 .
  • R 5 is -CF 3 .
  • a compound of Formula (I) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or
  • R 5 is Ci-6haloalkoxy.
  • R 5 is Ci-6haloalkoxy.
  • R 5 is -OCF 3 .
  • R 5 is -OCF 3 .
  • a compound of Formula (I) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or
  • R 6 is H.
  • R 6 is -CH 3 .
  • R 3 is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide,
  • R 3 is In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide,
  • R is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 10 is -0-Ci.6alkyl-C0 2 H.
  • R 10 is -OCH 2 C0 2 H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 10 is -OCH 2 CH 2 C0 2 H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 10 is -OCH 2 CH 2 CH 2 C0 2 H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 10 is -N(H)-Ci -6 alkyl-C0 2 H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 10 is -N(H)CH 2 C0 2 H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R is -N(H)CH 2 CH 2 C0 2 H.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 10 is -N(H)CH 2 CH 2 CH 2 C0 2 H.
  • R 10 is -0-C 3-8 cycloalkyl.
  • R 10 is -S0 2 R 17 and R 17 is Ci -6 alkyl.
  • Ci-6haloalkyl, or Ci-ehaloalkoxy In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is H. In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is -CN. In another embodiment is a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is halogen.
  • a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 5 is -CI.
  • R 5 is -F.
  • R 5 is Ci -6 haloalkyl.
  • R 6 is H.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • R 2 is H or Ci-ealkyl
  • R 4 is H, halogen, -OR 7 , Ci -6 alkyl, Ci -6 alkyl-OH, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -0-C 3- 8 cycloalkyl, -0-C 3-8 cycloalkyl-OH, -N(H)-Ci -6 alkyl-C0 2 H, -S0 2 R 17 , -C0 2 R 8 , -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -Ci -6 alkyl-C 2-9 heterocycloalkyl, C 6- i 0 aryl, C ⁇ .
  • C 3 - 8 cycloalkyl, C 2 - 9 heterocycloalkyl, -Ci- 6 alkyl-C 2 - 9 heterocycloalkyl, C 6 - 10 aryl, Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 ;
  • R 5 is H, -CN, halogen, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 haloalkoxy, or phenyl;
  • R 6 is H, halogen, or Ci -6 alkyl
  • R is H, Ci- 6 alkyl, Ci- 6 haloalkyl, C 3 - 8 cycloalkyl, C 2 - 9 heterocycloalkyl, C 6 - 10 aryl, or Ci.
  • gheteroaryl wherein C 2 - 9 heterocycloalkyl, C 6 - 10 aryl, or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 ;
  • each R 8 and each R 9 are independently selected from H and Ci -6 alkyl; or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;
  • R 12 is H, halogen, or
  • R 13 is H or C h alky.
  • each R 14 is independently selected from halogen, -OH, oxo, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 alkoxy, -Ci -6 alkyl-OH, C 3-8 cycloalkyl, -C0 2 R 8 , -C(0) R 8 R 9 , -C(0)-Ci -6 alkyl, -C(0)-Ci -6 alkyl-OH, -S0 2 -Ci -6 alkyl, -N(R 8 )S0 2 -Ci -6 alkyl, and -N(R 8 )C(0)-Ci -6 alkyl;
  • R 15 is Ci -6 alkyl or C 3-8 cycloalkyl
  • R 17 is Ci -6 alkyl or C 3-8 cycloalkyl
  • [0060] in another embodiment is a compound of Formula (la), or a solvate, hydrate, tautomer, ⁇ - oxide, stereoisomer, or pharmaceutically acceptable salt thereof, having the structure
  • a compound of Formula (la), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 .
  • a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is H.
  • a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is Ci -6 alkyl.
  • a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)C(0)R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is Ci- 6 alkyl.
  • R 1 is -N(CH 3 )C(0)R 15 and R 15 is
  • a compound of Formula (la) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is -CH 3 .
  • in another embodiment is a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(H)S0 2 R 15 and R 15 is C 3-8 cycloalkyl.
  • [0062] in another embodiment is a compound of Formula (la), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , Ci.
  • in another embodiment is a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , -N(H)-Ci-6alkyl-C0 2 H, Ci- 6 haloalkyl, -C(0) R 8 R 9 , C3- 8 cycloalkyl, C 2 - 9 heterocycloalkyl, or Ci.gheteroaryl, wherein C 2- gheterocycloalkyl or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 .
  • R 4 is halogen, -OR 7 , -N(H)-Ci-6alkyl-C0 2 H, Ci- 6 haloalkyl, -C(0) R 8 R 9 , C3- 8 cycloalkyl, C 2 - 9 heterocycloalkyl, or Ci.gheteroaryl,
  • R 4 is -CI.
  • a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 C0 2 H.
  • a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 CH 2 C0 2 H.
  • a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is unsubstituted C 3- 8 cycloalkyl or C 6- i 0 aryl optionally substituted with halogen.
  • a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl optionally substituted with halogen.
  • a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl substituted with halogen.
  • R 4 is C 2 - 9 heterocycloalkyl optionally substituted with 1 or 2 R 14 .
  • R 4 is C 4 - 5 heterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 4 - 5 heterocycloalkyl is a monocyclic heterocycloalkyl selected from pyrrolidine, piperidine, piperazine, and morpholine.
  • a compound of Formula (la) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-ciheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is a compound of Formula (la), or a solvate, h drate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is
  • in another embodiment is a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C2- 9 heteroaryl substituted with 1 or 2 R 14 .
  • a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is C 2-9 heteroaryl optionally substituted with 1 or 2 R 14 , wherein the C 2-9 heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine, indole, benzothiophene, benzofuran, and imidazopyridine.
  • R 4 is In another embodiment, a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is In another embodiment
  • R 5 is H, CN, halogen, Ci-ehaloalkyl, or Ci- 6 haloalkoxy.
  • R 5 is -CI.
  • R 6 is H.
  • R 12 is -CH 3 .
  • R 12 is -CH 3 .
  • R 13 is H.
  • a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is -CH 3 and R 13 is H.
  • a compound of Formula (la), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is Ci. 6 alkyl and R 13 is Ci- 6 alkyl.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • R 2 is H or Ci-ealkyl
  • Z is -S-, -0-, or -N(R 20 )-;
  • R 4 is H, halogen, -OR 7 , Ci -6 alkyl, Ci -6 alkyl-OH, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -0-C 3- 8 cycloalkyl, -0-C 3-8 cycloalkyl-OH, -N(H)-Ci -6 alkyl-C0 2 H, -S0 2 R 17 , -C0 2 R 8 , -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -Ci- 6 alkyl-C 2-9 heterocycloalkyl, C6-io ryl, Ci.
  • C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -Ci- 6 alkyl-C 2-9 heterocycloalkyl, C 6- i 0 aryl, Ci -9 heteroaryl are optionally substituted with 1 or 2 R 14 ;
  • R 5 is H, -CN, halogen, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 haloalkoxy, or phenyl;
  • R 6 is H, halogen, or Ci ⁇ alkyl
  • R is H, Ci- 6 alkyl, Ci-ehaloalkyl, C3- 8 cycloalkyl, C 2 - 9 heterocycloalkyl, C 6 - 10 aryl, or Ci. gheteroaryl, wherein C 2 - 9 heterocycloalkyl, C 6 - 10 aryl, or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 ;
  • each R 8 and each R 9 are independently selected from H and Ci -6 alkyl; or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;
  • R 12 is H, halogen, or
  • R 13 is H or C h alky.
  • each R 14 is independently selected from halogen, -OH, oxo, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 alkoxy, -Ci-ealkyl-OH, C 3-8 cycloalkyl, -C0 2 R 8 , -C(0) R 8 R 9 , -C(0)-Ci -6 alkyl, -C(0)-Ci -6 alkyl-OH, -S0 2 -Ci -6 alkyl, -N(R 8 )S0 2 -Ci -6 alkyl, and -N(R 8 )C(0)-Ci -6 alkyl;
  • R 15 is Ci -6 alkyl or C 3-8 cycloalkyl
  • R 17 is Ci -6 alkyl or C 3-8 cycloalkyl
  • R 20 is H or Ci-ealkyl
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 .
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is H.
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is Ci- 6 alkyl.
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is C 3-8 Cycloalkyl.
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is Ci -6 alkyl.
  • R 1 is -N(CH 3 )C(0)R 15 and R 15 is Ci -6 alkyl.
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 .
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)S0 2 R 15 and R 15 is
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is C 3-8 cycloalkyl.
  • R 4 is halogen, -OR 7 , Ci.
  • in another embodiment is a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , -N(H)-Ci -6 alkyl-C0 2 H, Ci -6 haloalkyl, -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, or Ci -9 heteroaryl, wherein C 2- gheterocycloalkyl or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 .
  • R 4 is -CI.
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)-Ci -6 alkyl-C0 2 H.
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 C0 2 H.
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 C0 2 H.
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 CH 2 C0 2 H.
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is unsubstituted C 3- scycloalkyl or C6- 10 aryl optionally substituted with halogen.
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl optionally substituted with halogen.
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl substituted with halogen.
  • R 4 is C2- 9 heterocycloalkyl optionally substituted with 1 or 2 R 14 .
  • R 4 is C 4-5 heterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 4-5 heterocycloalkyl is a monocyclic heterocycloalkyl selected from pyrrolidine, piperidine, piperazine, and morpholine.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-ciheterocycloalkyl is a bicyclic heterocycloalkyl.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs.gheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs.gheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs.gheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs.gheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • in another embodiment is a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C 2-9 heteroaryl substituted with 1 or 2 R 14 .
  • in another embodiment is a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C 2- 9heteroaryl optionally substituted with 1 or 2 R 14 , wherein the C 2- 9heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine, indole, benzothiophene, benzofuran, and imidazopyridine.
  • R 4 is In another embodiment, a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is In another embodiment
  • embodiment is a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is H, CN, halogen, Ci-ehaloalkyl, or Ci -6 haloalkoxy.
  • R 5 is H, CN, halogen, Ci-ehaloalkyl, or Ci -6 haloalkoxy.
  • R 5 is H, CN, halogen, Ci-ehaloalkyl, or Ci -6 haloalkoxy.
  • R 5 is a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is -CN.
  • R 5 is -CI.
  • R 5 is a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is -F.
  • R 5 is Ci- 6 alkyl.
  • R 5 is a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is -CH 3 .
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 5 is -OCF 3 .
  • R 6 is H.
  • R 13 is H.
  • R 12 is H and R 13 is H.
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is -CH 3 and R 13 is H.
  • a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is Ci. 6 alkyl and R 13 is Ci -6 alkyl.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • R 2 is H or C h alky.
  • Z is -S-, -0-, or -N(R 20 )-;
  • R 4 is H, halogen, -OR 7 , Ci -6 alkyl, Ci -6 alkyl-OH, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -O-C3- scycloalkyl, -0-C 3-8 cycloalkyl-OH, -N(H)-Ci -6 alkyl-C0 2 H, -S0 2 R 17 , -C0 2 R 8 , -C(0) R 8 R 9 ,
  • Ci -9 heteroaryl are optionally substituted with 1 or 2 R 14 ;
  • R 5 is H, -CN, halogen, Ci- 6 haloalkyl, Ci- 6 haloalkoxy, or phenyl;
  • R 7 is H, Ci -6 alkyl, Ci -6 haloalkyl, C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, C 6- i 0 aryl, or Ci.
  • each R 8 and each R 9 are independently selected from H and or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;
  • R 12 is H, halogen, or Ci -6 alkyl
  • R 13 is H or Ci -6 alkyl
  • each R 14 is independently selected from halogen, -OH, oxo, Ci-ehaloalkyl, Ci -6 alkoxy, -Ci -6 alkyl-OH, C 3-8 cycloalkyl, -C0 2 R 8 , -C(0) R 8 R 9 , -C(0)-Ci -6 alkyl, -C(0)-Ci -6 alkyl-OH, -S0 2 -Ci -6 alkyl, -N(R 8 )S0 2 -Ci -6 alkyl, and -N(R 8 )C(0)-Ci -6 alkyl;
  • R 15 is Ci- 6 alkyl or C 3-8 cycloalkyl
  • R 17 is Ci- 6 alkyl or C 3-8 cycloalkyl
  • R 20 is H or Ci -6 alkyl
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 .
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is H.
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is Ci -6 alkyl.
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)C(0)R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is Ci- 6 alkyl.
  • R 1 is -N(CH 3 )C(0)R 15 and R 15 is
  • a compound of Formula (Ic) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 .
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)S0 2 R and R is Ci- 6 alkyl.
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is -CH 3 .
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is C 3-8 cycloalkyl.
  • [0074] in another embodiment is a compound of Formula (Ic), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , Ci.
  • in another embodiment is a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , -N(H)-Ci -6 alkyl-C0 2 H, Ci- 6 haloalkyl, -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, or Ci.gheteroaryl, wherein C 2- gheterocycloalkyl or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 .
  • R 4 is -CI.
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)-Ci -6 alkyl-C0 2 H.
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 C0 2 H.
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 C0 2 H.
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 CH 2 C0 2 H.
  • R 4 is a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is -OR 7 .
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is unsubstituted C 3- 8 cycloalkyl or C 6- i 0 aryl optionally substituted with halogen.
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl optionally substituted with halogen.
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl substituted with halogen.
  • R 4 is C 2 - 9 heterocycloalkyl optionally substituted with 1 or 2 R 14 .
  • R 4 is C 4 - 5 heterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 4 - 5 heterocycloalkyl is a monocyclic heterocycloalkyl selected from pyrrolidine, piperidine, piperazine, and morpholine.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-ciheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-ciheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-ciheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-ciheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs.ghetero
  • In another embodiment is a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C 2-9 heteroaryl substituted with 1 or 2 R 14 .
  • R 4 is C 2- 9heteroaryl optionally substituted with 1 or 2 R 14 , wherein the C 2- 9heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine, indole, benzothiophene, benzofuran, and imidazopyridine.
  • R 5 is -CI.
  • R 5 is a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is -CH 3 .
  • R 12 is -CH 3 .
  • R 12 is -CH 3 .
  • R 13 is H.
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 13 is In another embodiment is a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 13 is -CH 3 . In another embodiment is a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 12 is H and R 13 is H.
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is -CH 3 and R 13 is H.
  • a compound of Formula (Ic), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is Ci. 6 alkyl and R 13 is Ci- 6 alkyl.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • R 2 is H or C h alky.
  • A is N or C(H);
  • Y is -CH 2 - or -C(0)-
  • R 4 is H, halogen, -OR 7 , Ci -6 alkyl, Ci -6 alkyl-OH, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -0-C 3- 8 cycloalkyl, -0-C 3-8 cycloalkyl-OH, -N(H)-Ci -6 alkyl-C0 2 H, -S0 2 R 17 , -C0 2 R 8 , -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -Ci- 6 alkyl-C 2-9 heterocycloalkyl, C6-io ryl, Ci. gheteroaryl, wherein C 3 - 8 cycloalkyl, C 2 - 9 heterocycloalkyl, -Ci- 6 alkyl-C 2 - 9 heterocycloalkyl,
  • Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 ;
  • R 5 is H, -CN, halogen, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 haloalkoxy, or phenyl;
  • R 6 is H, halogen, or Ci -6 alkyl
  • R 7 is H, Ci- 6 alkyl, Ci- 6 haloalkyl, C 3 - 8 cycloalkyl, C 2 - 9 heterocycloalkyl, C 6 - 10 aryl, or Ci.
  • gheteroaryl wherein C 2 - 9 heterocycloalkyl, C 6 - 10 aryl, or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 ;
  • each R 8 and each R 9 are independently selected from H and Ci -6 alkyl; or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;
  • R 12 is H, halogen, or
  • R 13 is H or C h alky.
  • each R 14 is independently selected from halogen, -OH, oxo, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 alkoxy, -Ci -6 alkyl-OH, C 3-8 cycloalkyl, -C0 2 R 8 , -C(0) R 8 R 9 , -C(0)-Ci -6 alkyl, -C(0)-Ci -6 alkyl-OH, -S0 2 -Ci -6 alkyl, -N(R 8 )S0 2 -Ci -6 alkyl, and -N(R 8 )C(0)-Ci -6 alkyl;
  • R 15 is Ci -6 alkyl or C 3-8 cycloalkyl
  • R 17 is Ci -6 alkyl or C 3-8 cycloalkyl
  • n 0 or 1
  • n 0 or 1
  • p 0, 1, or 2;
  • w 1 or 2;
  • [0077] in another embodiment is a compound of Formula (Id), or a solvate, hydrate, tautomer, ⁇ - oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(R 2 )C(0)R 15 .
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is Ci- 6 alkyl.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is Ci- 6 alkyl.
  • R 1 is -N(CH 3 )C(0)R 15 and R 15 is Ci- 6 alkyl.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 .
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)S0 2 R 15 and R 15 is Ci -6 alkyl.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is -CH 3 .
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, p is 1, and w is 1.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 0, n is 1, p is 1, and w is 2.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, p is 0, and w is 1.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein Y is -CH 2 -.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is H.
  • R 12 is -CH 3 .
  • R 12 is -CH 3 .
  • R 12 is -CH 3 .
  • R 13 is H.
  • R 12 is H and R 13 is H.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is -CH 3 and R 13 is H.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is Ci. 6 alkyl and R 13 is Ci- 6 alkyl.
  • [0082] in another embodiment is a compound of Formula (Id), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , Ci.
  • in another embodiment is a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , -N(H)-Ci-6alkyl-C0 2 H, Ci -6 haloalkyl, -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, or Ci -9 heteroaryl, wherein C 2- 9 heterocycloalkyl or Ci -9 heteroaryl are optionally substituted with 1 or 2 R 14 .
  • R 4 is -CI.
  • R 4 is a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is -N(H)-Ci.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is unsubstituted C 3- 8 cycloalkyl or C 6 -ioaryl optionally substituted with halogen.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl optionally substituted with halogen.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl substituted with halogen.
  • R 4 is C 2-9 heterocycloalkyl optionally substituted with 1 or 2 R 14 .
  • R 4 is C 4-5 heterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 4-5 heterocycloalkyl is a monocyclic heterocycloalkyl selected from pyrrolidine, piperidine, piperazine, and morpholine.
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs.gheterocycloalkyl is a bicyclic heterocycloalkyl.
  • a compound of Formula (Id) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or
  • R 4 is Cs-ciheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs.gheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or harmaceuticall acce table salt thereof, wherein R 4 is
  • In another embodiment is a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C 2-9 heteroaryl substituted with 1 or 2 R 14 .
  • a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is C 2- 9heteroaryl optionally substituted with 1 or 2 R 14 , wherein the C 2-9 heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine, indole, benzothiophene, benzofuran, and imidazopyridine.
  • R 4 is In another embodiment, a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is In another embodiment
  • embodiment is a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is H, CN, halogen, Ci -6 alkyl, Ci -6 haloalkyl, or Ci-6haloalkoxy.
  • R 5 is H, CN, halogen, Ci -6 alkyl, Ci -6 haloalkyl, or Ci-6haloalkoxy.
  • R 5 is -CI.
  • R 5 is a compound of Formula (Id), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is -CH 3 .
  • R 6 is H.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • R 2 is H or C h alky.
  • Y is -CH 2 - or -C(O)-;
  • Z is -S-, -0-, or -N(R 20 )-;
  • R 4 is H, halogen, -OR 7 , Ci -6 alkyl, Ci -6 alkyl-OH, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -O-C3.
  • Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 ;
  • R 5 is H, -CN, halogen, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 haloalkoxy, or phenyl;
  • R 6 is H, halogen, or Ci -6 alkyl
  • R 7 is H, Ci- 6 alkyl, Ci- 6 haloalkyl, C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, C 6 -ioaryl, or Ci.
  • gheteroaryl wherein C 2-9 heterocycloalkyl, C 6 -ioaryl, or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 ;
  • each R 8 and each R 9 are independently selected from H and Ci -6 alkyl; or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;
  • R 12 is H, halogen, or
  • R 13 is H or Ci -6 alkyl
  • each R 14 is independently selected from halogen, -OH, oxo, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 alkoxy, -Ci -6 alkyl-OH, C 3-8 cycloalkyl, -C0 2 R 8 , -C(0) R 8 R 9 , -C(0)-Ci -6 alkyl, -C(0)-Ci -6 alkyl-OH, -S0 2 -Ci -6 alkyl, -N(R 8 )S0 2 -Ci -6 alkyl, and -N(R 8 )C(0)-Ci -6 alkyl;
  • R 15 is Ci -6 alkyl or C 3-8 cycloalkyl
  • R 17 is Ci -6 alkyl or C 3-8 cycloalkyl
  • R 20 is H or Ci -6 alkyl
  • n 0 or 1
  • n 0 or 1
  • p 0, 1, or 2;
  • q 0, 1, or 2;
  • a compound of Formula (Ie), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 .
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is H.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is Ci- 6 alkyl.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)C(0)R 15 and R 15 is C 3-8 Cycloalkyl.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is Ci -6 alkyl.
  • R 1 is -N(CH 3 )C(0)R 15 and R 15 is Ci -6 alkyl.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 .
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)S0 2 R 15 and R 15 is Ci -6 alkyl.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is -CH 3 .
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, q is 1, and p is 1.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 0, n is 1, q is 2, and p is 1.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, q is 0, and p is 2.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, q is 1, and p is 0.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 0, n is 0, q is 2, and p is 1.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein Y is -CH 2 -.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein Y is -C(O)-.
  • R 12 is -CH 3 .
  • R 12 is -CH 3 .
  • R 12 is a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or
  • R 13 is H.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is H and R 13 is Ci -6 alkyl.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is H and R 13 is -CH 3 .
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is -CH 3 and R 13 is H.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is Ci. 6 alkyl and R 13 is Ci -6 alkyl.
  • [0089] in another embodiment is a compound of Formula (le), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , Ci.
  • in another embodiment is a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , -N(H)-Ci -6 alkyl-C0 2 H, Ci- 6 haloalkyl, -C(0)NR 8 R 9 , C 3-8 Cycloalkyl, C 2-9 heterocycloalkyl, or Ci.gheteroaryl, wherein C 2- gheterocycloalkyl or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 .
  • R 4 is -CI.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)-Ci -6 alkyl-C0 2 H.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 C0 2 H.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 C0 2 H.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 CH 2 C0 2 H.
  • in another embodiment is a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is -OR 7 and R 7 is unsubstituted C 3- 8 cycloalkyl or C 6- i 0 aryl optionally substituted with halogen.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is unsubstituted C 3-8 cycloalkyl.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl optionally substituted with halogen.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl substituted with halogen.
  • R 4 is C 2-9 heterocycloalkyl optionally substituted with 1 or 2 R 14 .
  • R 4 is C4- 5 heterocycloalkyl optionally substituted with 1 or 2 R , wherein the C4- 5 heterocycloalkyl is a monocyclic heterocycloalkyl selected from pyrrolidine, piperidine, piperazine, and morpholine.
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-gheterocycloalkyl is a bicyclic heterocycloalkyl.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-gheterocycloalkyl is a bicyclic heterocycloalkyl.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs.gheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or harmaceutically acceptable salt thereof, wherein R 4 is 3 ⁇ 4
  • In another embodiment is a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C2- 9 heteroaryl substituted with 1 or 2 R 14 .
  • in another embodiment is a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C 2 - 9 heteroaryl optionally substituted with 1 or 2 R 14 , wherein the C 2 - 9 heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine, indole, benzothiophene, benzofuran, and imidazopyridine.
  • R 4 is In another embodiment, a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is In another embodiment
  • embodiment is a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is H, CN, halogen, Ci -6 alkyl, Ci -6 haloalkyl, or Ci -6 haloalkoxy.
  • R 5 is H, CN, halogen, Ci -6 alkyl, Ci -6 haloalkyl, or Ci -6 haloalkoxy.
  • R 5 is -CI.
  • R 5 is a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is -F.
  • R 5 is Ci -6 alkyl.
  • R 5 is a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is -CH 3 .
  • a compound of Formula (le), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 5 is -OCF 3 .
  • R 6 is H.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • R 2 is H or Ci -6 alkyl
  • Y is -CH 2 - or -C(O)-;
  • Z is -S-, -0-, or -N(R 20 )-;
  • R 4 is H, halogen, -OR 7 , Ci -6 alkyl, Ci -6 alkyl-OH, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -0-C 3- scycloalkyl, -0-C 3-8 cycloalkyl-OH, -N(H)-Ci -6 alkyl-C0 2 H, -S0 2 R 17 , -C0 2 R 8 , -C(0)NR 8 R 9 ,
  • Ci -9 heteroaryl are optionally substituted with 1 or 2 R 14 ;
  • R 5 is H, -CN, halogen, Ci- 6 haloalkyl, Ci- 6 haloalkoxy, or phenyl;
  • R 7 is H, Ci -6 alkyl, Ci -6 haloalkyl, C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, C 6- i 0 aryl, or Ci.
  • each R 8 and each R 9 are independently selected from H and or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;
  • R 12 is H, halogen, or Ci -6 alkyl; R is H or Ci -6 alkyl;
  • each R 14 is independently selected from halogen, -OH, oxo, Ci-ehaloalkyl, Ci -6 alkoxy, -Ci -6 alkyl-OH, C 3-8 cycloalkyl, -C0 2 R 8 , -C(0) R 8 R 9 , -C(0)-Ci -6 alkyl, -C(0)-Ci -6 alkyl-OH, -S0 2 -Ci -6 alkyl, -N(R 8 )S0 2 -Ci -6 alkyl, and -N(R 8 )C(0)-Ci -6 alkyl;
  • R 15 is Ci- 6 alkyl or C 3-8 cycloalkyl
  • R 17 is Ci- 6 alkyl or C 3-8 cycloalkyl
  • R 20 is H or Ci -6 alkyl
  • n 0 or 1
  • n 0 or 1
  • p 0, 1, or 2;
  • q 0, 1, or 2;
  • [0091] in another embodiment is a compound of Formula (If), or a solvate, hydrate, tautomer, ⁇ - oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(R 2 )C(0)R 15 .
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is Ci -6 alkyl.
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)C(0)R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is Ci- 6 alkyl.
  • In another embodiment is a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is -CH 3 .
  • in another embodiment is a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is C 3-8 Cycloalkyl.
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)S0 2 R 15 .
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)S0 2 R 15 and R 15 is Ci- 6 alkyl.
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is -CH 3 .
  • In another embodiment is a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(H)S0 2 R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, q is 1, and p is 1.
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 0, n is 1, q is 2, and p is 1.
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, q is 0, and p is 2.
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 1, n is 1, q is 1, and p is 0.
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein m is 0, n is 0, q is 2, and p is 1.
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein Y is -CH 2 -.
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein Y is -C(O)-.
  • R 12 is -CH 3 .
  • R 12 is -CH 3 .
  • R 13 is H.
  • in another embodiment is a compound of Formula (If), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 12 is -CH 3 and R 13 is H.
  • [0096] in another embodiment is a compound of Formula (If), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , Ci.
  • in another embodiment is a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , -N(H)-Ci-6alkyl-C0 2 H, Ci -6 haloalkyl, -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, or Ci -9 heteroaryl, wherein C 2- 9 heterocycloalkyl or Ci -9 heteroaryl are optionally substituted with 1 or 2 R 14 .
  • R 4 is -CI.
  • R 4 is a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is -N(H)-Ci.
  • in another embodiment is a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is -N(H)CH 2 CH 2 CH 2 C0 2 H.
  • in another embodiment is a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is -C(0)NH 2 .
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is C 3-8 cycloalkyl.
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is unsubstituted C 3- 8 cycloalkyl or C 6 -ioaryl optionally substituted with halogen.
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl optionally substituted with halogen.
  • a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl substituted with halogen.
  • R 4 is C 2-9 heterocycloalkyl optionally substituted with 1 or 2 R 14 .
  • R 4 is C 4-5 heterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 4-5 heterocycloalkyl is a monocyclic heterocycloalkyl selected from pyrrolidine, piperidine, piperazine, and morpholine.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 5-9 heterocycloalkyl is a bicyclic heterocycloalkyl.
  • in another embodiment is a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is Cs-ciheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 5-9 heterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs-ciheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 5-9 heterocycloalkyl is a spirocyclic heterocycloalkyl.
  • a compound of Formula (If) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable
  • in another embodiment is a compound of Formula (If), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C 2- 9 heteroaryl optionally substituted with 1 or 2 R 14 , wherein the C 2-9 heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine, indole, benzothiophene, benzofuran, and imidazopyridine.
  • R 4 is C 2- 9 heteroaryl optionally substituted with 1 or 2 R 14 , wherein the C 2-9 heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine,
  • R 5 is -CH 3 .
  • R 5 is -CH 3 .
  • R 5 is Ci-6haloalkyl.
  • R 5 is Ci-6haloalkyl.
  • R 5 is -CF 3 .
  • R 5 is -CF 3 .
  • R 5 is Ci-6haloalkoxy.
  • R 5 is Ci-6haloalkoxy.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • R 2 is H or Ci -6 alkyl
  • A is N or C(H);
  • X is -0-, -N(R 16 )-, or -CH 2 N(R 16 )CH 2 -;
  • R 4 is H, halogen, -OR 7 , Ci -6 alkyl, Ci -6 alkyl-OH, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -0-C 3- scycloalkyl, -0-C 3-8 cycloalkyl-OH, -N(H)-Ci -6 alkyl-C0 2 H, -S0 2 R 17 , -C0 2 R 8 , -C(0)NR 8 R 9 ,
  • Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 ;
  • R 5 is H, -CN, halogen, Ci-ehaloalkyl, Ci-ehaloalkoxy, or phenyl;
  • R 6 is H, halogen, or
  • R 7 is H, Ci- 6 alkyl, Ci- 6 haloalkyl, C3- 8 cycloalkyl, C2- 9 heterocycloalkyl, C6- 10 aryl, or Ci.
  • each R 8 and each R 9 are independently selected from H and or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;
  • R 12 is H, halogen, or Ci -6 alkyl
  • R 13 is H or C h alky.
  • each R 14 is independently selected from halogen, -OH, oxo, Ci- 6 haloalkyl, Ci -6 alkoxy, -Ci-ealkyl-OH, C 3-8 cycloalkyl, -C0 2 R 8 , -C(0) R 8 R 9 , -C(0)-Ci -6 alkyl, -C(0)-Ci -6 alkyl-OH, -S0 2 -Ci -6 alkyl, -N(R 8 )S0 2 -Ci -6 alkyl, and -N(R 8 )C(0)-Ci -6 alkyl;
  • R 15 is Ci -6 alkyl or C 3-8 cycloalkyl
  • R 16 is H, Ci -6 alkyl, -C(0)-Ci -6 alkyl, or -CH 2 C0 2 H;
  • R 17 is Ci- 6 alkyl or C 3-8 cycloalkyl
  • v is 0 or 1 ;
  • Another embodiment is a compound of Formula (lb), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, having the
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, INT- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 .
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is H.
  • R 15 is Ci -6 alkyl.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is Ci- 6 alkyl.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is -CH 3 .
  • R 1 is -N(CH 3 )C(0)R 15 and R 15 is Ci- 6 alkyl.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 .
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)S0 2 R 15 and R 15 is Ci -6 alkyl.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is -CH 3 .
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein X is -0-.
  • X is -N(H)-.
  • X is -N(H)-.
  • X is -N(H)-.
  • X is -N(CH 3 )-.
  • X is -N(CH 3 )-.
  • X is -N(CH 3 )-.
  • X is -CH 2 N(R 16 )CH 2 -.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein A is N.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein v is 0.
  • [00103] in another embodiment is a compound of Formula (Ig), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , Ci.
  • in another embodiment is a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , -N(H)-Ci -6 alkyl-C0 2 H, Ci -6 haloalkyl, -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, or Ci -9 heteroaryl, wherein C 2- gheterocycloalkyl or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 .
  • R 4 is -CI.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)-Ci -6 alkyl-C0 2 H.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 C0 2 H.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 C0 2 H.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 CH 2 C0 2 H.
  • R 4 is a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is -OR 7 .
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is unsubstituted C 3- scycloalkyl or C6- 10 aryl optionally substituted with halogen.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl optionally substituted with halogen.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl substituted with halogen.
  • R 4 is C 2-9 heterocycloalkyl optionally substituted with 1 or 2 R 14 .
  • R 4 is C 4-5 heterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 4-5 heterocycloalkyl is a monocyclic heterocycloalkyl selected from pyrrolidine, piperidine, piperazine, and morpholine.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs.gheterocycloalkyl is a bicyclic heterocycloalkyl.
  • R 4 is Cs-ciheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs.gheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs-ciheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs.gheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs-ciheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs.gheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs-ciheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs.gheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs-ciheter
  • In another embodiment is a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C2- 9 heteroaryl substituted with 1 or 2 R 14 .
  • in another embodiment is a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C 2-9 heteroaryl optionally substituted with 1 or 2 R 14 , wherein the C2- 9 heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine, indole, benzothiophene, benzofuran, and imidazopyridine.
  • R 4 is In another embodiment, a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is In another embodiment
  • embodiment is a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is H, CN, halogen, Ci-ehaloalkyl, or Ci -6 haloalkoxy.
  • R 5 is H, CN, halogen, Ci-ehaloalkyl, or Ci -6 haloalkoxy.
  • R 5 is H, CN, halogen, Ci-ehaloalkyl, or Ci -6 haloalkoxy.
  • R 5 is a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is -CN.
  • R 5 is -CI.
  • R 5 is a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is -CH 3 .
  • R 6 is H.
  • R 12 is -CH 3 .
  • R 12 is -CH 3 .
  • R 12 is -CH 3 .
  • R 13 is H.
  • R 12 is H and R 13 is H.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is -CH 3 and R 13 is H.
  • a compound of Formula (Ig), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is Ci. 6 alkyl and R 13 is Ci -6 alkyl.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • R 2 is H or Ci-ealkyl
  • A is N or C(H);
  • X is -0-, -N(R 16 )-, or -CH 2 N(R 16 )CH 2 -;
  • R 4 is H, halogen, -OR 7 , Ci -6 alkyl, Ci -6 alkyl-OH, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -0-C 3- 8 cycloalkyl, -0-C 3-8 cycloalkyl-OH, -N(H)-Ci -6 alkyl-C0 2 H, -S0 2 R 17 , -C0 2 R 8 , -C(0) R 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -Ci- 6 alkyl-C 2-9 heterocycloalkyl, C 6 -io ryl, Ci.
  • C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -Ci- 6 alkyl-C 2-9 heterocycloalkyl, C 6- i 0 aryl, Ci -9 heteroaryl are optionally substituted with 1 or 2 R 14 ;
  • R 5 is H, -CN, halogen, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 haloalkoxy, or phenyl;
  • R 6 is H, halogen, or
  • R 7 is H, Ci- 6 alkyl, Ci-ehaloalkyl, C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, C 6 -ioaryl, or Ci.
  • each R 8 and each R 9 are independently selected from H and or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;
  • each R 14 is independently selected from halogen, -OH, oxo, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 alkoxy,
  • R 15 is Ci- 6 alkyl or C 3-8 cycloalkyl
  • R 16 is H, Ci -6 alkyl, -C(0)-Ci -6 alkyl, or -CH 2 C0 2 H;
  • R 17 is Ci -6 alkyl or C 3-8 cycloalkyl
  • v is 0 or 1; or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, ⁇ - oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 .
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is H.
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is Ci- 6 alkyl.
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is C 3-8 Cycloalkyl.
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is Ci -6 alkyl.
  • R 1 is -N(CH 3 )C(0)R 15 and R 15 is Ci -6 alkyl.
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 .
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)S0 2 R 15 and R 15 is Ci -6 alkyl.
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is -CH 3 .
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is C 3-8 cycloalkyl.
  • X is -N(H)-.
  • X is -N(H)-.
  • X is -N(H)-.
  • X is -N(CH 3 )-.
  • X is -N(CH 3 )-.
  • X is -N(CH 3 )-.
  • X is -CH 2 N(R 16 )CH 2 -.
  • X is -CH 2 N(R 16 )CH 2 -.
  • X is -CH 2 N(R 16 )CH 2 -.
  • X is -CH 2 N(R 16 )CH 2 -.
  • X is -CH 2 N(H)CH 2 -.
  • X is -CH 2 N(H)CH 2 -.
  • X is -CH 2 N(H)CH 2 -.
  • a compound of Formula (Ih) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein v is 0.
  • [00110] in another embodiment is a compound of Formula (Ih), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , Ci.
  • in another embodiment is a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , -N(H)-Ci- 6 alkyl-C0 2 H, Ci- 6 haloalkyl, -C(0)NR 8 R 9 , C 3-8 Cycloalkyl, C 2-9 heterocycloalkyl, or Ci.gheteroaryl, wherein C 2- 9 heterocycloalkyl or Ci -9 heteroaryl are optionally substituted with 1 or 2 R 14 .
  • R 4 is -CI.
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)-Ci -6 alkyl-C0 2 H.
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 C0 2 H.
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 C0 2 H.
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 CH 2 C0 2 H.
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is unsubstituted C 3- 8 cycloalkyl or C 6- i 0 aryl optionally substituted with halogen.
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl optionally substituted with halogen.
  • a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl substituted with halogen.
  • R 4 is C 2 - 9 heterocycloalkyl optionally substituted with 1 or 2 R 14 .
  • R 4 is C 4 - 5 heterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 4 - 5 heterocycloalkyl is a monocyclic heterocycloalkyl selected from pyrrolidine, piperidine, piperazine, and morpholine.
  • R 4 is Cs-gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-gheterocycloalkyl is a bicyclic heterocycloalkyl.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-gheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-gheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-gheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • a compound of Formula (Ih) or a solvate, h drate, tautomer N-oxide, stereoisomer, or harmaceuticall acce table salt thereof, is
  • In another embodiment is a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C 2-9 heteroaryl substituted with 1 or 2 R 14 .
  • in another embodiment is a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C 2- 9heteroaryl optionally substituted with 1 or 2 R 14 , wherein the C 2- 9heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine, indole, benzothiophene, benzofuran, and imidazopyridine.
  • R 4 is In another embodiment, a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is In another embodiment
  • embodiment is a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is H, CN, halogen, Ci -6 alkyl, Ci -6 haloalkyl, or Ci -6 haloalkoxy.
  • R 5 is H, CN, halogen, Ci -6 alkyl, Ci -6 haloalkyl, or Ci -6 haloalkoxy.
  • R 5 is -CI.
  • R 5 is a compound of Formula (Ih), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is -CH 3 .
  • R 6 is H.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • R 2 is H or Ci -6 alkyl
  • R 4 is H, halogen, -OR 7 , Ci -6 alkyl, Ci -6 alkyl-OH, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -0-C 3- 8 cycloalkyl, -0-C 3-8 cycloalkyl-OH, -N(H)-Ci -6 alkyl-C0 2 H, -S0 2 R 17 , -C0 2 R 8 , -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -Ci -6 alkyl-C 2-9 heterocycloalkyl, C 6- i 0 aryl, Ci. gheteroaryl, wherein C 3 - 8 cycloalkyl, C 2 - 9 heterocycloalkyl, -Ci- 6 alkyl-C 2 - 9 heterocycloalkyl,
  • Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 ;
  • R 5 is H, -CN, halogen, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 haloalkoxy, or phenyl;
  • R 6 is H, halogen, or Ci -6 alkyl
  • R 7 is H, Ci- 6 alkyl, Ci- 6 haloalkyl, C 3 - 8 cycloalkyl, C 2 - 9 heterocycloalkyl, C 6 - 10 aryl, or Ci.
  • gheteroaryl wherein C 2 - 9 heterocycloalkyl, C 6 - 10 aryl, or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 ;
  • each R 8 and each R 9 are independently selected from H and Ci -6 alkyl; or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;
  • each R 14 is independently selected from halogen, -OH, oxo, Ci-ehaloalkyl, Ci -6 alkoxy,
  • R 15 is Ci- 6 alkyl or C 3-8 cycloalkyl
  • R 17 is Ci- 6 alkyl or C 3-8 cycloalkyl
  • [00112] in another embodiment is a compound of Formula (Ii), or a solvate, hydrate, tautomer, ⁇ - oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(R 2 )C(0)R 15 .
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is Ci -6 alkyl.
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)C(0)R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is Ci- 6 alkyl.
  • In another embodiment is a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is -CH 3 .
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is C 3- 8Cycloalkyl.
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)S0 2 R 15 and R 15 is Ci-6alkyl.
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is -CH 3 .
  • In another embodiment is a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(H)S0 2 R 15 and R 15 is C 3-8 cycloalkyl.
  • [00113] in another embodiment is a compound of Formula (Ii), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , Ci.
  • in another embodiment is a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , -N(H)-Ci -6 alkyl-C0 2 H, Ci- 6 haloalkyl, -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, or Ci.gheteroaryl, wherein C 2- gheterocycloalkyl or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 .
  • R 4 is -CI.
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)-Ci -6 alkyl-C0 2 H.
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 C0 2 H.
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 C0 2 H.
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is - N(H)CH 2 CH 2 CH 2 C0 2 H.
  • R 4 is a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is -OR 7 .
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is unsubstituted C 3- 8 cycloalkyl or C 6- i 0 aryl optionally substituted with halogen.
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl optionally substituted with halogen.
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl substituted with halogen.
  • R 4 is C 2-9 heterocycloalkyl optionally substituted with 1 or 2 R 14 .
  • R 4 is C4- 5 heterocycloalkyl optionally substituted with 1 or 2 R , wherein the C4- 5 heterocycloalkyl is a monocyclic heterocycloalkyl selected from pyrrolidine, piperidine, piperazine, and morpholine.
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-gheterocycloalkyl is a bicyclic heterocycloalkyl.
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is Cs-gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 5-9 heterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is Cs-gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 5-9 heterocycloalkyl is a spirocyclic heterocycloalkyl.
  • in another embodiment is a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C 2- gheteroaryl optionally substituted with 1 or 2 R 14 , wherein the C 2- 9heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine, indole, benzothiophene, benzofuran, and imidazopyridine.
  • R 4 is C 2- gheteroaryl optionally substituted with 1 or 2 R 14 , wherein the C 2- 9heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine,
  • harmaceuticall acce table salt thereof wherein
  • a compound of Formula (Ii), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 5 is H, CN, halogen, Ci-ehaloalkyl, or Ci-ehaloalkoxy.
  • R 5 is -CH 3 .
  • R 5 is -CH 3 .
  • R 5 is Ci -6 haloalkyl.
  • R 5 is Ci -6 haloalkyl.
  • R 5 is -CF 3 .
  • R 5 is -CF 3 .
  • R 5 is Ci -6 haloalkoxy.
  • R 5 is Ci -6 haloalkoxy.
  • R 5 is -OCF 3 .
  • R 5 is -OCF 3 .
  • R 6 is H.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • R 2 is H or C h alky.
  • R 4 is H, halogen, -OR 7 , Ci -6 alkyl, Ci -6 alkyl-OH, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -0-C 3- scycloalkyl, -0-C 3-8 cycloalkyl-OH, -N(H)-Ci -6 alkyl-C0 2 H, -S0 2 R 17 , -C0 2 R 8 , -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -Ci- 6 alkyl-C 2-9 heterocycloalkyl, C6-io ryl, Ci.
  • R 5 is H, -CN, halog Ci-ehaloalkyl, Ci-ehaloalkoxy, or phenyl;
  • R 6 is H, halogen, or
  • R 7 is H, Ci -6 alkyl, Ci -6 haloalkyl, C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, C 6- i 0 aryl, or Ci.
  • each R 8 and each R 9 are independently selected from H and or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;
  • R is H, halogen, or
  • R 13 is H or Ci-ealkyl
  • each R 14 is independently selected from halogen, -OH, oxo, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 alkoxy, -Ci -6 alkyl-OH, C 3-8 cycloalkyl, -C0 2 R 8 , -C(0) R 8 R 9 , -C(0)-Ci -6 alkyl, -C(0)-Ci -6 alkyl-OH, -S0 2 -Ci -6 alkyl, -N(R 8 )S0 2 -Ci -6 alkyl, and -N(R 8 )C(0)-Ci -6 alkyl;
  • R 15 is Ci- 6 alkyl or C 3-8 cycloalkyl
  • R 17 is Ci -6 alkyl or C 3-8 cycloalkyl
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, ⁇ - oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 .
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is H.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is Ci -6 alkyl.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)C(0)R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is Ci- 6 alkyl.
  • In another embodiment is a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is -CH 3 .
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)S0 2 R 15 and R 15 is Ci- 6 alkyl.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 and R 15 is -CH 3 .
  • In another embodiment is a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(H)S0 2 R 15 and R 15 is C 3-8 cycloalkyl.
  • [00116] in another embodiment is a compound of Formula (Ij), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , Ci.
  • in another embodiment is a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , -N(H)-Ci- 6 alkyl-C0 2 H, Ci- 6 haloalkyl, -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, or Ci.gheteroaryl, wherein C 2- 9 heterocycloalkyl or Ci -9 heteroaryl are optionally substituted with 1 or 2 R 14 .
  • R 4 is halogen, -OR 7 , -N(H)-Ci- 6 alkyl-C0 2 H, Ci- 6 haloalkyl, -C(0)NR 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, or Ci.gheteroaryl, wherein C 2- 9 heterocyclo
  • R 4 is -CI.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)-Ci- 6 alkyl-C0 2 H.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 C0 2 H.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 C0 2 H.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is - N(H)CH 2 CH 2 CH 2 C0 2 H.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is unsubstituted C 3- 8 cycloalkyl or C 6- i 0 aryl optionally substituted with halogen.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl optionally substituted with halogen.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl substituted with halogen.
  • R 4 is C 2-9 heterocycloalkyl optionally substituted with 1 or 2 R 14 .
  • R 4 is C4- 5 heterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 4-5 heterocycloalkyl is a monocyclic heterocycloalkyl selected from pyrrolidine, piperidine, piperazine, and morpholine.
  • R 4 is Cs-ciheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 5-9 heterocycloalkyl is a bicyclic heterocycloalkyl.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is Cs-ciheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C5- 9 heterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is C 2- gheteroaryl optionally substituted with 1 or 2 R 14 , wherein the C 2 - 9 heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine, indole, benzothiophene, benzofuran, and imidazopyridine.
  • in another embodiment is a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or harmaceutically acceptable salt thereof, wherein
  • R 5 is -CH 3 .
  • R 5 is -CH 3 .
  • R 5 is Ci -6 haloalkyl.
  • R 5 is Ci -6 haloalkyl.
  • R 5 is -CF 3 .
  • R 5 is -CF 3 .
  • R 5 is Ci -6 haloalkoxy.
  • R 5 is Ci -6 haloalkoxy.
  • R 5 is -OCF 3 .
  • R 5 is -OCF 3 .
  • R 6 is H.
  • a compound of Formula (Ij) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 6 is halogen.
  • a compound of Formula (Ij) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 6 is halogen.
  • a compound of Formula (Ij) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 6 is halogen.
  • R 12 is -CH 3 .
  • R 12 is -CH 3 .
  • R 12 is -CH 3 .
  • R 13 is H.
  • R 12 is H and R 13 is H.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is -CH 3 and R 13 is H.
  • a compound of Formula (Ij), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is and R 13 is Ci. 6 alkyl.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • R 2 is H or C h alky.
  • R 4 is H, halogen, -OR 7 , Ci -6 alkyl, Ci -6 alkyl-OH, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 haloalkyl, -O-C3- scycloalkyl, -0-C 3-8 cycloalkyl-OH, -N(H)-Ci -6 alkyl-C0 2 H, -S0 2 R 17 , -C0 2 R 8 , -C(0) R 8 R 9 , C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -Ci -6 alkyl-C 2-9 heterocycloalkyl, C 6- i 0 aryl, Ci.
  • gheteroaryl wherein C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, -Ci -6 alkyl-C 2-9 heterocycloalkyl, C 6 -ioaryl, Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 ;
  • R 5 is H, -CN, halogen, Ci- 6 haloalkyl, Ci- 6 haloalkoxy, or phenyl;
  • R 6 is H, halogen, or Ci -6 alkyl
  • R 7 is H, Ci -6 alkyl, Ci -6 haloalkyl, C 3-8 cycloalkyl, C 2-9 heterocycloalkyl, C 6- i 0 aryl, or Ci.
  • gheteroaryl wherein C 2-9 heterocycloalkyl, C6-ioaryl, or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 ;
  • each R 8 and each R 9 are independently selected from H and Ci -6 alkyl; or R 8 and R 9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;
  • each R 14 is independently selected from halogen, -OH, oxo, Ci-ehaloalkyl, Ci -6 alkoxy,
  • R 15 is Ci -6 alkyl or C 3-8 cycloalkyl
  • R 17 is Ci- 6 alkyl or C 3-8 cycloalkyl
  • R 18 and R 19 are independently selected from H and wherein R 18 and R 19 are not both H;
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, ⁇ - oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 .
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is H.
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is Ci -6 alkyl.
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is Ci- 6 alkyl.
  • R 1 is -N(CH 3 )C(0)R 15 and R 15 is
  • a compound of Formula (Ik) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)S0 2 R 15 .
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)S0 2 R 15 and R 15 is
  • In another embodiment is a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(H)S0 2 R 15 and R 15 is C 3-8 cycloalkyl.
  • [00120] in another embodiment is a compound of Formula (Ik), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , Ci.
  • in another embodiment is a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is halogen, -OR 7 , -N(H)-Ci-6alkyl-C0 2 H, Ci- 6 haloalkyl, -C(0) R 8 R 9 , C3- 8 cycloalkyl, C 2 - 9 heterocycloalkyl, or Ci.gheteroaryl, wherein C 2- gheterocycloalkyl or Ci.gheteroaryl are optionally substituted with 1 or 2 R 14 .
  • R 4 is -CI.
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)-Ci -6 alkyl-C0 2 H.
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 C0 2 H.
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 C0 2 H.
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -N(H)CH 2 CH 2 CH 2 C0 2 H.
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is unsubstituted C 3- 8 cycloalkyl or C 6- i 0 aryl optionally substituted with halogen.
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl optionally substituted with halogen.
  • a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 4 is -OR 7 and R 7 is phenyl substituted with halogen.
  • R 4 is C 2 - 9 heterocycloalkyl optionally substituted with 1 or 2 R 14 .
  • R 4 is C 4 - 5 heterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the C 4 - 5 heterocycloalkyl is a monocyclic heterocycloalkyl selected from pyrrolidine, piperidine, piperazine, and morpholine.
  • a compound of Formula (Ik) or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or
  • R 4 is Cs.gheterocycloalkyl optionally substituted with 1 or 2 R 14 , wherein the Cs-ciheterocycloalkyl is a spirocyclic heterocycloalkyl.
  • R 4 is a compound of Formula (Ik), or a solvate, h drate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is
  • In another embodiment is a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C2- 9 heteroaryl substituted with 1 or 2 R 14 .
  • in another embodiment is a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is C 2-9 heteroaryl optionally substituted with 1 or 2 R 14 , wherein the C 2-9 heteroaryl is selected from pyrrole, furan, thiophene, thiazole, pyrazole, oxazole, oxadiazole, thiadiazole, pyridine, pyrimidine, pyrazine, indole, benzothiophene, benzofuran, and imidazopyridine.
  • R 4 is In another embodiment, a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 4 is In another embodiment
  • embodiment is a compound of Formula (Ik), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 5 is H, CN, halogen, Ci-ehaloalkyl, or Ci- 6 haloalkoxy.
  • R 5 is H, CN, halogen, Ci-ehaloalkyl, or Ci- 6 haloalkoxy.
  • R 5 is -CI.
  • R 5 is Ci- 6 alkyl.
  • R 6 is H.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • R 2 is H or Ci-ealkyl
  • R 5 is H, -CN, halogen, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 haloalkoxy, or phenyl;
  • R 6 is H, halogen, or Ci -6 alkyl
  • R 10 is -0-Ci.ehaloalkyl, -0-Ci -6 alkyl-C0 2 H, -0-C 3-8 cycloalkyl, -0-C 3-8 cycloalkyl-C0 2 H, -N(H)-
  • R 12 is H, halogen, or Ci -6 alkyl
  • R 13 is H or C h alky.
  • R 15 is Ci- 6 alkyl or C 3-8 cycloalkyl
  • R 17 is Ci- 6 alkyl or C 3-8 cycloalkyl
  • a compound of Formula (II), or a solvate, hydrate, tautomer, ⁇ - oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 .
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is H.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R 15 is Ci- 6 alkyl.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(H)C(0)R 15 and R is -CH 3 .
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)C(0)R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is Ci- 6 alkyl.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(R 2 )C(0)R 15 and R 2 is -CH 3 .
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is Ci- 6 alkyl.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is -CH 3 .
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is -N(CH 3 )C(0)R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)S0 2 R 15 .
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 1 is - N(H)S0 2 R 15 and R 15 is
  • In another embodiment is a compound of Formula (H), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R 1 is -N(H)S0 2 R 15 and R 15 is C 3-8 cycloalkyl.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 10 is -0-Ci -6 alkyl-C0 2 H.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 10 is -OCH 2 C0 2 H.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 10 is -OCH 2 CH 2 CH 2 C0 2 H.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 10 is -N(H)-Ci -6 alkyl-C0 2 H.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R is -N(H)CH 2 C0 2 H.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 10 is -N(H)CH 2 CH 2 C0 2 H.
  • R 10 is -0-C 3-8 cycloalkyl.
  • R 10 is -S0 2 R 17 and R 17 is
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 10 is -S0 2 R 17 and R 17 is -CH 3 .
  • R 5 is -F.
  • R 5 is Ci-6haloalkyl.
  • R 6 is H.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is H.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is In another embodiment is a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or
  • R 12 is -CH 3 .
  • R 12 is -CH 3 .
  • R 12 is -CH 3 .
  • R 13 is H.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is H and R 13 is Ci- 6 alkyl.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is H and R 13 is -CH 3 .
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N- oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is -CH 3 and R 13 is H.
  • a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof wherein R 12 is Ci -6 alkyl and R 13 is Ci. 6 alkyl.
  • R 1 is -N(R 2 )C(0)R 15 or -N(H)S0 2 R 15 ;
  • R 2 is H or Ci -6 alkyl
  • R 5 is H, -CN, halog Ci-ehaloalkyl, Ci-ehaloalkoxy, or phenyl;
  • R 6 is H, halogen, or
  • R 10 is -0-Ci -6 haloalkyl, -0-Ci -6 alkyl-C0 2 H, -0-C 3-8 cycloalkyl, -0-C 3-8 cycloalkyl-C0 2 H, -N(H)- Ci -6 alkyl-C0 2 H, or -S0 2 R 17 ;
  • R is H, halogen, or
  • R is H or Ci -6 alkyl
  • R is Ci -6 alkyl or C 3-8 cycloalkyl; or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2018/033964 2017-05-23 2018-05-22 Pyrazole magl inhibitors Ceased WO2018217809A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
EP18805515.6A EP3634404B1 (en) 2017-05-23 2018-05-22 Pyrazole magl inhibitors
ES18805515T ES3005265T3 (en) 2017-05-23 2018-05-22 Pyrazole magl inhibitors
CA3065898A CA3065898A1 (en) 2017-05-23 2018-05-22 Pyrazole magl inhibitors
PE2019002453A PE20200293A1 (es) 2017-05-23 2018-05-22 Inhibidores pirazolicos de magl
RU2019137094A RU2019137094A (ru) 2017-05-23 2018-05-22 Ингибиторы magl на основе пиразола
CN201880033866.9A CN110678177B (zh) 2017-05-23 2018-05-22 吡唑magl抑制剂
MX2019014041A MX2019014041A (es) 2017-05-23 2018-05-22 Inhibidores pirazolicos de magl.
US16/615,746 US11149037B2 (en) 2017-05-23 2018-05-22 Pyrazole MAGL inhibitors
BR112019024488-3A BR112019024488A2 (pt) 2017-05-23 2018-05-22 inibidores de pirazol magl
CR20190537A CR20190537A (es) 2017-05-23 2018-05-22 Inhibidores pirazólicos de magl
JP2019565399A JP7162622B2 (ja) 2017-05-23 2018-05-22 ピラゾールｍａｇｌ阻害剤
KR1020197037406A KR20200010366A (ko) 2017-05-23 2018-05-22 피라졸 magl 저해제
AU2018273888A AU2018273888A1 (en) 2017-05-23 2018-05-22 Pyrazole MAGL inhibitors
EA201992504A EA201992504A1 (ru) 2017-05-23 2018-05-22 Ингибиторы magl на основе пиразола
DO2019000295A DOP2019000295A (es) 2017-05-23 2019-11-20 Inhibidores pirazólicos de magl
CONC2019/0013016A CO2019013016A2 (es) 2017-05-23 2019-11-21 Inhibidores pirazólicos de magl
PH12019502646A PH12019502646A1 (en) 2017-05-23 2019-11-22 Pyrazole magl inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762510223P 2017-05-23 2017-05-23
US62/510,223 2017-05-23

Publications (1)

Publication Number Publication Date
WO2018217809A1 true WO2018217809A1 (en) 2018-11-29

Family

ID=64397012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/033964 Ceased WO2018217809A1 (en) 2017-05-23 2018-05-22 Pyrazole magl inhibitors

Country Status (23)

Country Link
US (1) US11149037B2 (enExample)
EP (1) EP3634404B1 (enExample)
JP (1) JP7162622B2 (enExample)
KR (1) KR20200010366A (enExample)
CN (1) CN110678177B (enExample)
AU (1) AU2018273888A1 (enExample)
BR (1) BR112019024488A2 (enExample)
CA (1) CA3065898A1 (enExample)
CL (1) CL2019003398A1 (enExample)
CO (1) CO2019013016A2 (enExample)
CR (1) CR20190537A (enExample)
DO (1) DOP2019000295A (enExample)
EA (1) EA201992504A1 (enExample)
EC (1) ECSP19083923A (enExample)
ES (1) ES3005265T3 (enExample)
JO (1) JOP20190267A1 (enExample)
MA (1) MA50405A (enExample)
MX (1) MX2019014041A (enExample)
NI (1) NI201900120A (enExample)
PE (1) PE20200293A1 (enExample)
PH (1) PH12019502646A1 (enExample)
RU (1) RU2019137094A (enExample)
WO (1) WO2018217809A1 (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266497B2 (en) 2017-05-23 2019-04-23 Abide Therapeutics, Inc. Pyrazole MAGL inhibitors
US10583137B2 (en) 2015-12-02 2020-03-10 The Scripps Research Institute Triazole DAGLα inhibitors
WO2021005034A1 (en) * 2019-07-09 2021-01-14 F. Hoffmann-La Roche Ag New heterocyclic compounds
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
US11149037B2 (en) 2017-05-23 2021-10-19 H. Lundbeck A/S Pyrazole MAGL inhibitors
US11530189B2 (en) 2012-01-06 2022-12-20 H. Lundbecka/S Carbamate compounds and methods of making and using same
US11608347B2 (en) 2018-01-08 2023-03-21 Hoffmann-La Roche Inc. Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors
US11691975B2 (en) 2016-11-16 2023-07-04 H. Lundbecka/S MAGL inhibitors
US12053459B2 (en) 2021-06-26 2024-08-06 Cedilla Therapeutics, Inc. CDK2 inhibitors and methods of using the same
US12065445B2 (en) 2021-01-29 2024-08-20 Cedilla Therapeutics, Inc. CDK2 inhibitors and methods of using the same
US12286421B2 (en) 2021-12-29 2025-04-29 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (MAGL)
US12378231B2 (en) 2023-02-13 2025-08-05 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof
WO2025221154A1 (en) 2024-04-17 2025-10-23 Captor Therapeutics S.A. Klhdc2 (kelch domain-containing protein 2) ligase ligands

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
WO2022057928A1 (zh) * 2020-09-18 2022-03-24 上海医药集团股份有限公司 一种羰基杂环类化合物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010074588A2 (en) 2008-12-24 2010-07-01 BIAL - PORTELA & Cª, S.A. Pharmaceutical compounds
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
WO2015179559A2 (en) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2016014975A2 (en) 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
US20170029390A1 (en) 2015-07-31 2017-02-02 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
WO2017087854A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3308130A (en) 1962-04-26 1967-03-07 Du Pont N-disubstituted carbamyl pyrazoles
EP1309591B1 (en) 2000-08-14 2007-01-24 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
MXPA04007995A (es) * 2002-02-19 2004-11-26 Teva Pharma Desolvatacion de solvatos de hemicalcio de atorvastatina.
SE0300705D0 (sv) 2003-03-14 2003-03-14 Biolipox Ab New compounds
US9108930B2 (en) 2011-04-06 2015-08-18 The Scripps Research Institute N1- and N2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
US9624170B2 (en) 2013-12-26 2017-04-18 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors
BR112017001353B1 (pt) * 2014-07-23 2022-02-22 Baker Hughes Incorporated Aparelho e método para monitorar escala orgânica de fundo de poço e intervir em um poço de produção
WO2017087863A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
US10583137B2 (en) 2015-12-02 2020-03-10 The Scripps Research Institute Triazole DAGLα inhibitors
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
LT3630744T (lt) 2017-05-23 2023-03-10 H. Lundbeck A/S Pirazolo magl inhibitoriai

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
WO2010074588A2 (en) 2008-12-24 2010-07-01 BIAL - PORTELA & Cª, S.A. Pharmaceutical compounds
WO2015179559A2 (en) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2016014975A2 (en) 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
US20170029390A1 (en) 2015-07-31 2017-02-02 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
WO2017087854A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", vol. in, 2005, JOHN WILEY & SONS
ADVANCED DRUG DELIVERY REVIEWS, vol. 19, 1996, pages 115
BERGE S.M. ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1997, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104
FUHRHOP, J.PENZLIN G: "Organic Synthesis: Concepts, Methods, Starting Materials", 1994, JOHN WILEY & SONS
H. O. HOUSE: "Modern Synthetic Reactions", 1972, W. A. BENJAMIN, INC.
LAROCK, R. C.: "Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia", 1999, JOHN WILEY & SONS
LONG, J. Z ET AL., NAT. CHEM. BIOL., vol. 5, pages 37 - 44
NIPHAKIS, M. J., ACS CHEM. NEUROSCI., 2011
S. R. SANDLER ET AL.: "Organic Functional Group Preparations", 1983, JOHN WILEY & SONS, INC.
See also references of EP3634404A4
SOLOMONS, T. W. G.: "Modern Carbonyl Chemistry", 2000, JOHN WILEY & SONS
STOWELL, J.C: "Intermediate Organic Chemistry", 1993, WILEY-INTERSCIENCE
T. L. GILCHRIST: "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 1992, WILEY-INTERSCIENCE

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11530189B2 (en) 2012-01-06 2022-12-20 H. Lundbecka/S Carbamate compounds and methods of making and using same
US12018004B2 (en) 2012-01-06 2024-06-25 H. Lundbeck A/S Carbamate compounds and methods of making and using same
US10583137B2 (en) 2015-12-02 2020-03-10 The Scripps Research Institute Triazole DAGLα inhibitors
US11691975B2 (en) 2016-11-16 2023-07-04 H. Lundbecka/S MAGL inhibitors
US11149037B2 (en) 2017-05-23 2021-10-19 H. Lundbeck A/S Pyrazole MAGL inhibitors
US10266497B2 (en) 2017-05-23 2019-04-23 Abide Therapeutics, Inc. Pyrazole MAGL inhibitors
US11655217B2 (en) 2017-05-23 2023-05-23 H. Lundbeck A/S Pyrazole MAGL inhibitors
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
US12258340B2 (en) 2017-05-23 2025-03-25 H. Lundbeck A/S Pyrazole MAGL inhibitors
US11608347B2 (en) 2018-01-08 2023-03-21 Hoffmann-La Roche Inc. Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors
WO2021005034A1 (en) * 2019-07-09 2021-01-14 F. Hoffmann-La Roche Ag New heterocyclic compounds
US12065445B2 (en) 2021-01-29 2024-08-20 Cedilla Therapeutics, Inc. CDK2 inhibitors and methods of using the same
US12053459B2 (en) 2021-06-26 2024-08-06 Cedilla Therapeutics, Inc. CDK2 inhibitors and methods of using the same
US12286421B2 (en) 2021-12-29 2025-04-29 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (MAGL)
US12378231B2 (en) 2023-02-13 2025-08-05 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof
WO2025221154A1 (en) 2024-04-17 2025-10-23 Captor Therapeutics S.A. Klhdc2 (kelch domain-containing protein 2) ligase ligands
WO2025219579A1 (en) 2024-04-17 2025-10-23 Captor Therapeutics S.A. Klhdc2 (kelch domain-containing protein 2) ligase ligands

Also Published As

Publication number Publication date
EP3634404C0 (en) 2024-11-20
ES3005265T3 (en) 2025-03-14
DOP2019000295A (es) 2020-02-28
CR20190537A (es) 2020-04-15
BR112019024488A2 (pt) 2020-08-18
ECSP19083923A (es) 2020-01-31
EP3634404A4 (en) 2020-10-14
EA201992504A1 (ru) 2020-07-10
US11149037B2 (en) 2021-10-19
CA3065898A1 (en) 2018-11-29
MX2019014041A (es) 2020-09-25
CO2019013016A2 (es) 2020-04-01
EP3634404B1 (en) 2024-11-20
PH12019502646A1 (en) 2020-06-01
CL2019003398A1 (es) 2020-03-20
MA50405A (fr) 2020-08-26
CN110678177B (zh) 2023-06-13
JP2020521767A (ja) 2020-07-27
JOP20190267A1 (ar) 2019-11-18
NI201900120A (es) 2020-05-15
RU2019137094A (ru) 2021-06-23
PE20200293A1 (es) 2020-02-05
JP7162622B2 (ja) 2022-10-28
EP3634404A1 (en) 2020-04-15
AU2018273888A1 (en) 2019-12-05
KR20200010366A (ko) 2020-01-30
US20200087304A1 (en) 2020-03-19
CN110678177A (zh) 2020-01-10

Similar Documents

Publication Publication Date Title
WO2018217809A1 (en) Pyrazole magl inhibitors
EP3377060B1 (en) Pyrazole derivatives, processes for their preparation and uses thereof
EP3675848B1 (en) Spirocycle compounds and methods of making and using same
EP3630744B1 (en) Pyrazole magl inhibitors
EP3541820A1 (en) Magl inhibitors
EP3515897A1 (en) Piperazine carbamates and methods of making and using same
US12258340B2 (en) Pyrazole MAGL inhibitors
EP3595665A1 (en) Dual magl and faah inhibitors
HK40115819A (en) Dual magl and faah inhibitors
HK40095793A (en) Pyrazole magl inhibitors
HK40101669A (en) Dual magl and faah inhibitors
HK40032870A (en) Spirocycle compounds and methods of making and using same
HK40032870B (en) Spirocycle compounds and methods of making and using same
HK40026545A (en) Pyrazole magl inhibitors
HK40026545B (en) Pyrazole magl inhibitors
EA047826B1 (ru) Ингибиторы magl на основе пиразола
HK40010192B (en) Piperazine carbamates as modulators of magl and/or abhd6 and their use
HK40010192A (en) Piperazine carbamates as modulators of magl and/or abhd6 and their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18805515

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3065898

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 15220

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: DZP2019000558

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: NC2019/0013016

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2019565399

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019024488

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018273888

Country of ref document: AU

Date of ref document: 20180522

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197037406

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2019137094

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 2018805515

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018805515

Country of ref document: EP

Effective date: 20200102

WWP Wipo information: published in national office

Ref document number: NC2019/0013016

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 112019024488

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20191121